Middle and long term efficacy of radiofrequency ablation combined with immunotherapy in the treatment of hepatocellular carcinoma
10.3760/cma.j.issn.1008-6706.2014.20.019
- VernacularTitle:射频消融联合免疫疗法治疗肝癌的中远期疗效分析
- Author:
Zilong WU
;
Jiangang CAI
;
Guosheng MO
;
Zhigang HUANG
- Publication Type:Journal Article
- Keywords:
Liver neoplasms;
Radiofrequency ablation;
Immunotherapy
- From:
Chinese Journal of Primary Medicine and Pharmacy
2014;(20):3092-3094,3095
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the efficacy and safety of percutaneous radiofrequency ablation combined with immunotherapy in the treatment of hepatocellular carcinoma .Methods A total of 124 patients with liver cancer were randomly divided into the two groups .60 cases in the control group were given immunity treatment alone ,while 64 cases in the observation group were treated by percutaneous radiofrequency ablation combined with immune therapy . The middle and long term curative effect of two groups was observed .Results After treatment,the tumor diameter, serum alpha fetoprotein (AFP) and carcino-embryonic antigen (CEA) levels in the two groups were significantly decreased(t=4.867,P=0.005;t=5.175,P=0.004;t=3.155,P=0.025;t=4.845,P=0.005;t=4.031,P=0.010;t=2.668,P=0.044),but the declining degree of the observation group was better than the control group (t=4.119,P=0.009;t=3.621,P=0.015;t=3.492,P=0.017).The total effective rates and disease control rates of the observation group were 53.1%,78.1%,which were significantly higher than 28.3%,46.7%in the control group (χ2 =11.290,P=0.010;χ2 =21.290,P=0.000).The 1-year,3-year,5-year survival rates of the observation group were 60.9%,31.3%,12.5%,those of the control group were 21.7%,5.0%,0.0%,the middle and long term sur-vival rates of the observation group were significantly higher than the control group (χ2 =21.935,P=0.000;χ2 =56.452,P=0.000;χ2 =40.516,P=0.000).No statistically significant differences in the CD 4+,CD8+,CD4+/CD8+, IL-12 and other indicators between the two groups before treatment ,but these indicators in the observation group were significantly improved after treatment (t =4.515,P =0.006;t =10.014,P =0.000;t =5.217,P =0.003). Conclusion Combination of percutaneous radiofrequency ablation and immunotherapy in the treatment of hepatocell-lular carcinoma has exact effect and with advantages of less adverse reaction , good safety , which can significantly improve the quality of life and survival rate of patients ,it has good clinical application value .
